Payment overview · 2025
General Payments
$729.74
38 reported records · 11 companies
Healthcare provider profile · identity verified
Faaiza Arshad
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant · HAYTI, MO · NPI 1144887001
Verified facts
What the public records show
CMS Open Payments records show Faaiza Arshad received $729.74 in general payments during 2025 across 38 reported records.
Alkermes, Inc. accounted for 42.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Gemtesa, Rexulti, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Symbicort by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 137 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Trelegy Ellipta by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Rexulti by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Rexulti by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $306.53 | 42.0% | 17 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $138.91 | 19.0% | 6 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $66.01 | 9.1% | 3 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $62.41 | 8.6% | 3 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $40.16 | 5.5% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $34.05 | 4.7% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $17.50 | 2.4% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $17.41 | 2.4% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $16.70 | 2.3% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.72 | 2.1% | 1 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $14.34 | 2.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $729.74 | 38 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $306.53 | 17 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $306.53 | 17 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $188.73 | 8 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $62.41 | 3 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $40.16 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $34.05 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $34.05 | 2 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $17.50 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $17.41 | 1 | 2025 |
Source payment records
|
|||||
| UZEDY Normalized: uzedy |
Drug | Teva Pharmaceuticals USA, Inc. | $16.70 | 1 | 2025 |
Source payment records
|
|||||
| ABILIFY ASIMTUFII Normalized: abilify asimtufii |
Drug | Otsuka America Pharmaceutical, Inc. | $16.19 | 1 | 2025 |
Source payment records
|
|||||
| ABILIFY MAINTENA Normalized: abilify maintena |
Drug | Otsuka America Pharmaceutical, Inc. | $16.19 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $15.72 | 1 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $14.34 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 20 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 52 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
45 | 23 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
137 | 26 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
52 | 24 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
20 | 11 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
20 | 11 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 465 | 135 |
| Amlodipine Besylate | Amlodipine Besylate | 327 | 97 |
| Pantoprazole Sodium | Pantoprazole Sodium | 311 | 99 |
| Lisinopril | Lisinopril | 307 | 84 |
| Levothyroxine Sodium | Levothyroxine Sodium | 292 | 71 |
| Gabapentin | Gabapentin | 228 | 77 |
| Clopidogrel | Clopidogrel Bisulfate | 198 | 56 |
| Potassium Chloride | Potassium Chloride | 183 | 36 |
| Furosemide | Furosemide | 167 | 53 |
| Metformin Hcl | Metformin Hcl | 160 | 40 |
| Omeprazole | Omeprazole | 154 | 52 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 152 | 77 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 149 | 58 |
| Ibuprofen | Ibuprofen | 148 | 43 |
| Metoprolol Tartrate | Metoprolol Tartrate | 144 | 41 |
| Baclofen | Baclofen | 142 | 48 |
| Divalproex Sodium | Divalproex Sodium | 139 | 23 |
| Eliquis | Apixaban | 137 | 26 |
| Trazodone Hcl | Trazodone Hcl | 134 | 46 |
| Mirtazapine | Mirtazapine | 121 | 36 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 120 | 42 |
| Carvedilol | Carvedilol | 116 | 35 |
| Olanzapine | Olanzapine | 115 | 15 |
| Tamsulosin Hcl | Tamsulosin Hcl | 110 | 28 |
| Prazosin Hcl | Prazosin Hcl | 103 | 18 |
| Levetiracetam | Levetiracetam | 100 | 18 |
| Famotidine | Famotidine | 98 | 26 |
| Benztropine Mesylate | Benztropine Mesylate | 96 | 18 |
| Buspirone Hcl | Buspirone Hcl | 93 | 26 |
| Hydralazine Hcl | Hydralazine Hcl | 93 | 24 |
| Losartan Potassium | Losartan Potassium | 93 | 33 |
| Topiramate | Topiramate | 93 | 33 |
| Metoprolol Succinate | Metoprolol Succinate | 91 | 38 |
| Donepezil Hcl | Donepezil Hcl | 86 | 24 |
| Quetiapine Fumarate | Quetiapine Fumarate | 86 | 23 |
| Montelukast Sodium | Montelukast Sodium | 82 | 30 |
| Aripiprazole | Aripiprazole | 81 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 80 | 26 |
| Hydrochlorothiazide | Hydrochlorothiazide | 77 | 35 |
| Duloxetine Hcl | Duloxetine Hcl | 76 | 19 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 70 | 13 |
| Amoxicillin | Amoxicillin | 69 | 60 |
| Clonidine Hcl | Clonidine Hcl | 66 | 22 |
| Sertraline Hcl | Sertraline Hcl | 66 | 20 |
| Ondansetron Hcl | Ondansetron Hcl | 64 | 34 |
| Meclizine Hcl | Meclizine Hcl | 62 | 15 |
| Meloxicam | Meloxicam | 60 | 28 |
| Ventolin Hfa | Albuterol Sulfate | 60 | 27 |
| Azithromycin | Azithromycin | 59 | 52 |
| Fluticasone Propionate | Fluticasone Propionate | 59 | 27 |
| Simvastatin | Simvastatin | 59 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 58 | 46 |
| Tizanidine Hcl | Tizanidine Hcl | 55 | 14 |
| Risperidone | Risperidone | 52 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 52 | 20 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 52 | 24 |
| Dicyclomine Hcl | Dicyclomine Hcl | 51 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 49 | 16 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 48 | 43 |
| Xifaxan | Rifaximin | 48 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 47 | 19 |
| Ezetimibe | Ezetimibe | 47 | 12 |
| Jardiance | Empagliflozin | 46 | 11 |
| Symbicort | Budesonide/Formoterol Fumarate | 45 | 23 |
| Allopurinol | Allopurinol | 44 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 44 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 44 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 43 | 36 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 42 | 23 |
| Naproxen | Naproxen | 42 | 15 |
| Oxcarbazepine | Oxcarbazepine | 42 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 40 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 39 | 14 |
| Lamotrigine | Lamotrigine | 38 | 12 |
| Linzess | Linaclotide | 38 | 14 |
| Nifedipine Er | Nifedipine | 38 | 12 |
| Nystatin | Nystatin | 38 | 20 |
| Spironolactone | Spironolactone | 38 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 37 | 11 |
| Levofloxacin | Levofloxacin | 36 | 30 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 36 | 14 |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 36 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 36 | suppressed |
| Xarelto | Rivaroxaban | 35 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 34 | suppressed |
| Paliperidone Er | Paliperidone | 34 | suppressed |
| Acyclovir | Acyclovir | 33 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 33 | 12 |
| Fluconazole | Fluconazole | 32 | 26 |
| Glipizide | Glipizide | 32 | suppressed |
| Prednisone | Prednisone | 31 | 25 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 31 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 30 | suppressed |
| Celecoxib | Celecoxib | 30 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 29 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 28 | 12 |
| Januvia | Sitagliptin Phosphate | 27 | 15 |
| Primidone | Primidone | 27 | suppressed |
| Vascepa | Icosapent Ethyl | 27 | suppressed |
| Cilostazol | Cilostazol | 26 | suppressed |
| Myrbetriq | Mirabegron | 25 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 24 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 23 | suppressed |
| Haloperidol | Haloperidol | 23 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 23 | 11 |
| Lactulose | Lactulose | 23 | suppressed |
| Trulicity | Dulaglutide | 23 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 23 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 22 | 20 |
| Bupropion Xl | Bupropion Hcl | 22 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 22 | suppressed |
| Finasteride | Finasteride | 22 | suppressed |
| Tradjenta | Linagliptin | 22 | suppressed |
| Atenolol | Atenolol | 21 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 21 | suppressed |
| Nystop | Nystatin | 21 | suppressed |
| Torsemide | Torsemide | 21 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 21 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 20 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | 14 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | 17 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 20 | suppressed |
| Rexulti | Brexpiprazole | 20 | 11 |
| Risperdal Consta | Risperidone Microspheres | 20 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 20 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | 12 |
| Memantine Hcl | Memantine Hcl | 19 | suppressed |
| Nyamyc | Nystatin | 19 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Westab Plus | Pnv,calcium 72/Iron/Folic Acid | 19 | suppressed |
| Metronidazole | Metronidazole | 18 | 16 |
| Ozempic | Semaglutide | 18 | 12 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 16 | 11 |
| Gemtesa | Vibegron | 16 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 15 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 15 | 12 |
| Metoclopramide Hcl | Metoclopramide Hcl | 15 | suppressed |
| Sucralfate | Sucralfate | 15 | suppressed |
| Glimepiride | Glimepiride | 14 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 14 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 14 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Dexamethasone Sodium Phosphate | Dexamethasone Sodium Phosphate | 13 | 13 |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Junel Fe | Norethindrone-E.Estradiol-Iron | 13 | suppressed |
| Levemir Flexpen | Insulin Detemir | 13 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 13 | suppressed |
| Paroxetine Cr | Paroxetine Hcl | 13 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 12 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 12 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
| Scopolamine | Scopolamine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $729.74 · 38 records | Alkermes, Inc. | ABILIFY ASIMTUFII, ABILIFY MAINTENA, ARISTADA, COBENFY, FANAPT, FARXIGA, GEMTESA, LYBALVI, OTEZLA, QUTENZA, REPATHA, REXULTI, TRELEGY ELLIPTA, UZEDY | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error